Biotechnology firm Septerna has raised $150m in a Series B funding round to develop its pipeline of new oral small molecule therapies that act on G protein-coupled receptors (GPCRs).
New investor RA Capital Management led the round, with current investors Third Rock Ventures, Invus, Catalio Capital Management, Samsara BioCapital and BVF Partners among others taking part.
RA Capital Management partner Jake Simson will join the board of directors of Septerna.
The proceeds will be utilised for portfolio development and to progress its lead parathyroid hormone 1 receptor (PTH1R) programme to clinical proof-of-mechanism.
This PTH1R agonist programme is being developed to treat hypoparathyroidism, a condition marked by reduced levels of PTH.
The company will also use the funds to advance the preclinical development of a second thyroid-stimulating hormone receptor-targeting programme and other initial-stage assets.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Septerna co-founder and CEO Jeffrey Finer stated: “This milestone marks an important transition for Septerna to a product-development company, with plans to advance our lead PTH1R programme to clinical proof-of-mechanism while building out a multi-product pipeline for a range of diseases.
“This is an exciting time for GPCR drug development, and we are eager to move our novel products toward clinical development.”